Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on on healthcare or medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. For up-to-date information on other healthcare topics, please consult the relevant reliable sources or an healthcare expert, such as a physician etc.
 BACK TO LIST

Laboratory Report

Patient
Name: Roberts, Carly
DOB: 10-DEC-1969 (Age: 56)
Gender: female
Address:
2 Price meadow
LE4 Mitchellborough (United Kingdom)
ID: 9384-259853-9 (ECI)
Report
Date: 12-NOV-2023
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
St Matthews Health & Community Centre
Malabar Road 62-66
LE1 4 Leicester (United Kingdom)
Specimen
Collected: 12-NOV-2023

Hematology

Test 12-NOV-2023 Reference Range Unit
Leukocytes [#/volume] in Blood by Automated count 7.5 4.0 - 11.0 10*3/uL
Erythrocytes [#/volume] in Blood by Automated count 5.6 H 4.2 - 5.4 10*6/uL
Hemoglobin [Mass/volume] in Blood 12.9 12 - 16 g/dL
Hematocrit [Volume Fraction] of Blood by Automated count 37.4 36 - 46 %
MCV [Entitic mean volume] in Red Blood Cells by Automated count 96.1 80 - 100 fL
MCH [Entitic mass] by Automated count 31.1 27 - 33 pg
MCHC [Entitic Mass/volume] in Red Blood Cells by Automated count 33.7 32 - 36 g/dL
Erythrocyte [DistWidth] in Blood by Automated count 14.1 11.5 - 14.5 %
Platelets [#/volume] in Blood by Automated count 429.1 150 - 450 10*3/uL

Chemistry

Test 12-NOV-2023 Reference Range Unit
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 1211.0 H 0 - 450 pg/mL
Glucose [Mass/volume] in Serum or Plasma 79.0 65 - 99 mg/dL
Urea nitrogen [Mass/volume] in Serum or Plasma 11.3 7 - 20 mg/dL
Creatinine [Mass/volume] in Serum or Plasma 0.8 0.5 - 1.1 mg/dL
Calcium [Mass/volume] in Serum or Plasma 9.0 8.6 - 10.3 mg/dL
Sodium [Moles/volume] in Serum or Plasma 143.2 135 - 145 mmol/L
Potassium [Moles/volume] in Serum or Plasma 5.2 H 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Serum or Plasma 106.8 98 - 110 mmol/L
Carbon dioxide, total [Moles/volume] in Serum or Plasma 20.2 L 22 - 32 mmol/L
Protein [Mass/volume] in Serum or Plasma 7.1 6.6 - 8.3 g/dL
Albumin [Mass/volume] in Serum or Plasma 4.0 3.5 - 5.2 g/dL
Bilirubin.total [Mass/volume] in Serum or Plasma 0.4 0.1 - 1.2 mg/dL
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 50.6 32 - 91 U/L
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 40.8 7 - 56 U/L
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 6.7 L 10 - 40 U/L
Magnesium [Mass/volume] in Serum or Plasma 2.3 H 1.7 - 2.2 mg/dL
Cholesterol [Mass/volume] in Serum or Plasma 145.7 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 147.4 0 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 86.8 0 - 100 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 29.5 L 40 - 60 mg/dL
Hemoglobin A1c/Hemoglobin.total in Blood 5.1 4.0 - 5.6 %
Troponin I.cardiac [Mass/volume] in Serum or Plasma by High sensitivity method 0.0 0.0 - 19.9 pg/mL
Ferritin [Mass/volume] in Serum or Plasma 132.8 13 - 150 ug/L
Iron [Mass/volume] in Serum or Plasma 53.7 50 - 170 ug/dL
Iron binding capacity [Mass/volume] in Serum or Plasma 380.1 250 - 450 ug/dL
Iron saturation [Mass Fraction] in Serum or Plasma 30.0 15 - 50 %

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows markedly elevated NT-proBNP, suggestive of possible heart failure or cardiac dysfunction. Mild hyperkalemia, elevated magnesium, and low total CO₂ may indicate renal or metabolic disturbances. HDL cholesterol is low, increasing cardiovascular risk. Other parameters, including blood count, renal, and liver function, are within or near normal limits. Clinical correlation and further cardiac and metabolic evaluation are recommended.